Stelara (Ustekinumab)
Launch:
Stelara was launched by Janssen Pharmaceuticals (a division of Johnson & Johnson) in 2009.
Manufacturer:
Janssen Pharmaceuticals (Johnson & Johnson)
Global Sales in 2023:
Stelara generated approximately $10 billion in global sales in 2023.

Why It’s the Best:
Stelara is a monoclonal antibody used to treat autoimmune conditions such as psoriasis, Crohn’s disease, and ulcerative colitis. It works by targeting interleukin-12 and interleukin-23, proteins involved in inflammatory processes. Its long-lasting effects and ability to manage symptoms of severe autoimmune conditions with fewer side effects compared to other treatments have made Stelara a preferred option for many patients.